Question

.. What was the FDA's response to concerns about prescribing/dispensing mifepristone following the Supreme Court's decision in Dobbs?

They decided to leave it up to the states
They changed the REMS for mifepristone to make it more difficult to prescribe
They commissioned a study to determine the impact of the decision on prescribing
They announced that states may not ban mifepristone based on disagreement with FDA's expert judgment about its
safety and efficacy

Answer 1

The FDA announced that states may not ban mifepristone based on disagreement with FDA's expert judgment about its safety and efficacy.

Step-by-step explanation:

The FDA's response to concerns about prescribing/dispensing mifepristone following the Supreme Court's decision in Dobbs was that they announced that states may not ban mifepristone based on disagreement with FDA's expert judgment about its safety and efficacy. This means that the FDA reaffirmed their support for the use of mifepristone and acknowledged that states cannot prohibit its use solely because they disagree with the FDA's evaluation of its safety and effectiveness.

Learn more about FDA's response to concerns about mifepristone following Supreme Court's decision in Dobbs